Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-242 with or without G-CSF in severe alcoholic hepatitis and acute-on-chronic liver failure
ISRCTN36798599Phase 2Recruiting
- Sponsor
- Yaqrit
- Start
- Jun 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of resatorvid and granulocyte colony-stimulating factor in alcoholic hepatitis (AH) and acute-on-chronic liver failure (ACLF), sponsored by Yaqrit. Primary endpoints: Treatment-emergent adverse events or serious adverse events through Day 14, Discontinuation due to adverse event through Day 14 and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
resatorvidgranulocyte colony-stimulating factor
03
Conditions
alcoholic hepatitis (AH)acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on ISRCTN36798599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36798599.